+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Piperacillin/Tazobactam (ZOSYN)

Piperacillin/Tazobactam (ZOSYN)

Infectious Diseases in Obstetrics and Gynecology 4(5): 258-262

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 055010535

Download citation: RISBibTeXText

PMID: 18476104

Related references

Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 133(6): 351-358, 2009

Piperacillin/Tazobactam (Zosyn). Ajn, American Journal of Nursing 94(6): 54-55, 1994

FDA approved new drug bulletin: piperacillin/tazobactam (zosyn), salmeterol xinafoate (serevent). Rn 57(8): 49-52, 1994

Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Therapeutics and Clinical Risk Management 4(2): 303-314, 2008

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease 61(1): 76-79, 2008

Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas. Journal of the American Osteopathic Association 105(1): 25-26, 2005

Multicenter randomized clinical trial of piperacillin plus tazobactam vs piperacillin plus tazobactam and amikacin in the treatment of severe generalized peritonitis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 602, 1998

Multiple dose pharmacokinetics of piperacillin and tazobactam metabolites following piperacillin-tazobactam administration in healthy and renally impaired subjects. Pharmaceutical Research (New York) 9(10 Suppl. ): S326, 1992

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli. Antimicrobial Agents and ChemoTherapy 60(12): 7527-7529, 2016

Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstetrics and Gynecology 83(2): 280-286, 1994

Synergistic effect of polyethylenimine plus piperacillin/tazobactam on clinical Pseudomonas aeruginosa isolates resistant to piperacillin/tazobactam. Annals of Microbiology 56(4): 345-348, 2006

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains. Antimicrobial Agents and ChemoTherapy 61(7):, 2017

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology 28(4): 311-320, 2011

Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. Journal of Antimicrobial ChemoTherapy 61(3): 757-758, 2008

A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group. Revista Espanola de Quimioterapia 11(2): 139-146, 1998